A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia (Q58414303)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 August 2013

Language	Label	Description	Also known as
English	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia	scientific article published on 16 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

phase I clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Carsten Müller-Tidow

1

object named as

Carsten Müller-Tidow

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Gesine Bug

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Michael Lübbert

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Alwin Krämer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jürgen Krauter

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

David Nachbaur

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Holger Fritsch

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Gerd Munzert

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Pilar Garin-Chesa

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Frank Fleischer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tillmann Taube

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Wolfgang E Berdel

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hartmut Döhner

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

0 references

publication date

16 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

163

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

214-222

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Therapeutic advances in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

AML in older patients: are we making progress?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

The potential role of Aurora kinase inhibitors in haematological malignancies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12518

21 January 2018

Identifiers

10.1111/BJH.12518

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24033250%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58414303&oldid=2138403871"